• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

    26.45 -0.78 (-2.86%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 605,324
    Open 26.90
    Bid (Size) 25.75 (500)
    Ask (Size) 27.50 (200)
    Prev. Close 27.23
    Today's Range 26.41 - 27.54
    52wk Range 9.320 - 44.60
    Shares Outstanding 41,793,412
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. ↗
    This clinical-stage biotech focused on immunology therapies reported a notable insider buy amid a year of strong stock performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire

    Performance

    YTD
    -23.3%
    -23.3%
    1 Month
    +51.4%
    +51.4%
    3 Month
    +18.8%
    +18.8%
    6 Month
    +59.2%
    +59.2%
    1 Year
    +170.2%
    +170.2%

    More News

    Read More
    News headline image
    Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
    From Zenas BioPharma
    Via GlobeNewswire
    Why Is ZBIO Stock Falling Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
    Via The Motley Fool
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zenas BioPharma, Inc. - Common Stock publicly traded?
    Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
    What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
    Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
    The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
    What is the current price of Zenas BioPharma, Inc. - Common Stock?
    The current price of Zenas BioPharma, Inc. - Common Stock is 26.45
    When was Zenas BioPharma, Inc. - Common Stock last traded?
    The last trade of Zenas BioPharma, Inc. - Common Stock was at 07/06/26 04:00 PM ET
    What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?
    The market capitalization of Zenas BioPharma, Inc. - Common Stock is 1.11B
    How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?
    Zenas BioPharma, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.